BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1470@azbio.org DTSTART;TZID=America/Phoenix:20200507T120000 DTEND;TZID=America/Phoenix:20200507T130000 DTSTAMP:20200430T131600Z URL:https://www.azbio.org/events/cracking-the-commercialization-code-4-def ining-steps-that-could-unlock-your-life-science-technologys-commercializat ion-potential SUMMARY:Cracking the Commercialization Code: 4 defining steps that could un lock your life science technology’s commercialization potential - Webina r - 7 May 20 12:00 DESCRIPTION:\nCracking the Commercialization Code\n4 defining steps that co uld unlock your life science technology’s commercialization potential\nM ay 7\, 2020\n\n12:00 pm–1:30 pm PDT/AZ \;\nREGISTER\nYou believe in your science and that it will generate a safe and effective product\; unfo rtunately\, that alone might not ensure it reaches patients. From understa nding your market and regulatory needs to payor reimbursement and clinical adoption\, we aim to provide an aerial view to help define your pathway t hrough the commercialization maze. In this session\, we take you through t he nuances of the 4 key steps on the path to commercialization:\n\n Globa l markets \;\n Regulatory agencies\n Payor reimbursement\n Clinicia n adoption\n\nJoin us for practical steps to help maneuver the maze. Like most things for life science entrepreneurs\, starting early can help smoot h the road.\nPanelists\nJOEL BATTS\n\nCo-Founder\, President\, \;Telos Partners LLC\n\n​Joel is a medical device industry veteran\, with 20 ye ars of leadership experience developing scientific and regulatory strategi es for start-ups to large cap companies. He has delivered >\;$100 millio n return on investment by delivering FDA approvals for Class II and Class III devices in the musculoskeletal and wound care spaces. He has published and presented the results of pre-clinical and clinical science in journal s such as American Journal of Sports Medicine\, American Journal of Orthop aedics\, and venues such as the American College of Foot and Ankle Surgeon s.\n\nIn 2010\, he led a business development team in the application of a novel biologic material to osteoporotic patients for reducing the inciden ce of hip fractures. After conducting early-phase trials and developing th e scientific and regulatory strategy\, the team sold the technology for $3 0 million. He has also overseen key areas of investment and integration fo r four major acquisitions. Joel’s interests include the transformation o f healthcare in developing countries of Africa\, in partnership with the v ision of LifeNet International.\n\nJoel earned a BS in exercise science fr om the University of Florida and an MA in bioethics and health policy from Loyola University Chicago Stritch School of Medicine.\n\nPETER T. BIGELOW \n\nPresident\, \;xCell Strategic Consulting LLC\n\nPeter is the Presi dent of xCell Strategic Consulting\, a consulting firm to the Pharmaceutic al Industry. xCell provides consulting services in the areas of Drug Devel opment\, Outsourcing\, and Supply Chain. In addition\, xCell Provides advi ce and support for M&\;A in the Pharmaceutical Services Industry. Prior to founding xCell\, Peter served as Division President of Qualitest\, End o Pharmaceutical’s Generic Drug Division. He also served as the Presiden t of North America Commercial Operations and CEO at Patheon Pharmaceutical s. Patheon is a leading Contract Manufacturing and Contract Research Organ ization which at the time was Publicly Traded and had $700 million in reve nues and 5000 employees.\n\nPrior to joining Patheon\, Peter spent 14 year s with Wyeth Pharmaceuticals. While at Wyeth\, he oversaw a significant po rtion of the Manufacturing and Supply Chain organization including Consume r Products such as Advil and Centrum Vitamins\, Branded Drug Products and Vaccines such as Prevnar. He also oversaw Global Engineering and expansion programs to support drug manufacturing and Research and Development.\n\nP eter also spent 14 years at SmithKline Beecham (now GlaxoSmithKline) befor e joining Wyeth. His assignments included significant international projec t work in Europe and the Far East and operations experience with injectabl e product manufacturing.\n\nPeter is a member of the Global Pharmaceutical Manufacturing Leadership Forum of the ISPE and is a frequent speaker at I ndustry events. He serves as the Chairman of the Board of Trustees of the Pharma\, Biopharma Outsourcing Association (PBOA)\; a non-profit trade ass ociation that represents the needs and interests of Pharmaceutical Contrac t Development &\; Manufacturing Organizations (CDMOs). Peter is on the Board of Frontida Laboratories and on the Board of CASA Youth Services – a non profit organization serving the needs of Children in the Foster Car e environment. He has a BS in Mechanical Engineering from Villanova Univer sity and an MBA from Philadelphia University. Peter and his wife Lynn resi de in Valley Forge\, Pennsylvania.\n\n​LUCIA MOKRES\, DVM\n\n​CEO and Principal\, \;Araneae Biotech Consulting LLC\n\nDr. Lucia Mokres coach es current and aspiring life science founders through Stakeholder Ecosyste m DiscoverySM\, a robust and intensive model for establishing product-mark et fit and understanding the needs of the complex landscape of decision ma kers that will determine their path to market.  Using an evidence-base d approach to their product development plan enables founders to gain trac tion and develop an investable technology and business model.  The ski lls learned in her training can be used again and again to start new compa nies\, develop new pipeline products\, and rapidly adapt to changing econo mic\, regulatory\, and competitive landscapes.\n\nPrior to establishing he r consultancy\, Dr. Mokres was the Chief Medical Officer of EpiBiome\, Inc .\, where she led EpiBiome through the NSF Innovation Corps and several ot her incubators and accelerators. Dr. Mokres is an invited speaker national ly and internationally on the challenges faced by early stage companies se eking regulatory approval.\n\nIn her spare time\, Dr. Mokres mentors life science company founders through the Springboard Enterprises and Californi a Life Sciences Institute advisory programs\, and mentors women completing their PhD and postdoctoral studies on behalf of the Association for Women in Science.\n\nMICHAEL K. O'BRIEN\, PhD\n\nCEO\, \;NGT BioPharma Cons ultants\; \;President and CEO of NGT BioPharma\n\nConsultants\, Dr. O ’Brien is recognized as a forward-thinking innovator in the biopharmaceu tical industry. As the VP Pharmaceutical Sciences Technology &\; Innova tion at Pfizer Pharmaceuticals\, he conceived and collaborated on the desi gn\, fabrication and implementation of a portable\, continuous\, miniature and modular (PCMM) oral solid dose manufacturing facility that was built off-site and assembled in a warehouse\, with the capability to transfer an d reassemble the facility at other sites. The PCMM facility won the 2016 I SPE Facility of The Year Award. Dr. O’Brien previously served as the act ing head of a large biopharma chemical development organization\, where he oversaw and managed cGMP Kg-laboratories\, pilot plants\, API external su pply groups\, environmental\, health and safety (EHS) teams\, as well as t he Synthesis R&\;D group.\n\nAn agent of change who strategically align s stakeholders to ensure executive support for status quo transformation\, Dr. O’Brien’s expertise extends to development of digital\, analytica l\, drug substance and drug product platform technologies\, which\, when i mplemented\, automate critical industry processes\, operations and oversig ht. He was named an Industry Influencer on The Medicine Maker 2019 Power L ist and has more than 55 publications\, presentations and patents.\n\nAVER Y SONNEBERG\, PhD\n\nPrincipal\, \;Two Bear Capital\n\n​As a Princip al at Two Bear Capital\, Avery focuses on the technology\, science\, and b usiness case behind investment decisions. With a PhD in Bioengineering fro m UC San Diego\, Avery joins the firm after a senior engineering role in t he Life Science Innovation group at Becton Dickinson. Avery's expertise\, through both academic and industry experience\, is in anticipating\, under standing\, and solving the roadblocks between transformational technologie s and life-changing products. Avery enjoys hiking\, biking\, climbing\, an d camping\, especially with his wife and three young sons.\nAgenda\n12:00 pm - 12:45 pm \;  \;- Presentation\n\n12:45 pm - 1:30 pm - \;P anel Discussion and Audience Q &\; A LOCATION:Webinar\, Anywhere\, USA\, United States X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Anywhere\, USA\, United Sta tes;X-APPLE-RADIUS=100;X-TITLE=Webinar:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20190508T120000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR